Obesity and endocrine disorders in women taking valproate for epilepsy

Annals of Neurology

Volumn 39, Issue 5, 1996, Pages 579-584

  Isojärvi, Jouko I T ^a   Laatikainen, Timo J ^a   Knip, Mikael ^a   Pakarinen, Arto J ^b   Juntunen, Kaisa T S ^a   Myllylä, Vilho V ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; INSULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VALPROIC ACID;

ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; BODY WEIGHT; CARBAMAZEPINE; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; ENDOCRINE SYSTEM DISEASES; EPILEPSY; EVALUATION STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; OBESITY; POLYCYSTIC OVARY SYNDROME; PREVALENCE; SEX HORMONE-BINDING GLOBULIN; SOMATOMEDINS; TESTOSTERONE; TIME FACTORS; VALPROIC ACID;

EID: 0029884009     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390506     Document Type: Article

References (24)

1. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388
2. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69
3. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-581
4. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 1993;39:1-16
5. Conover CA, Phillip DKL, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and non-obese humans. J Clin Endocrinol Metab 1992;74:1355-1360
6. Pasquali R, Casimirri F, Plate L, Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm Metab Res 1989;22:303-306
7. Singh A, Hamilton-Fairley D, Koistinen R, et al. Effect of insulin-like growth factor type I (IGF I) and insulin on the secretion of sex hormone binding globulin and IGF I binding protein (IBP I) by human hepatoma cells. J Endocrinol 1990; 124:1-3
8. Pekonen F, Laatikainen T, Buyalos R, Rutanen E-M. Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease. Fertil Steril 1989;51:972-975
9. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213-230
10. Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981;22:489-501
11. Swanson M, Saurbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981;9:219-222
12. Herbert V, Lan KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol 1965;25:1375-1384
13. Pelconen F, Kärkkäinen T, Tanner P, et al. A monoclonal antibody-based immunoradiometric assay for low molecular weight insulin-like growth factor binding protein/placental protein 12. J Immunoassay 1989;10:325-337
14. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670
15. Kusunoki M, Yamamura T, Ichii S, et al. The effects of sodium valproate on plasma somatostatin and insulin in humans. J Clin Endocrinol Metab 1988;67:1060-1063
16. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor 1 hypothesis. Fertil Steril 1992;58:655-666
17. Coiro V, Capretti L, Bianconi L, et al. Reduction of baclofen-, but not sodium valproate-induced growth hormone release in type 1 diabetic men. Horm Metab Res 1991;23:600-604
18. Blum WF, Ranke MB. Plasma IGFBP-3 levels as clinical indicators. In: Spencer EM, ed. Modern concepts of insulin-like growth factors. New York: Elsevier, 1991:381-393
19. Petra P. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 1991;40:735-773
20. Schwander JC, Hauri C, Zapf J, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence of growth hormone status. Endocrinology 1983;113:297-305
21. Blum WF, Jenne EW, Reppin F, et al. Insulin-like growth factor I(IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989;125:766-772
22. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37:119-126
23. Dahlgren E, Janson PO, Johansson S, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513
24. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;33: 853-861